更新于：2024-11-11
188Re-HEDP
铼[Re-188]依替膦酸盐
更新于：2024-11-11
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段无进展临床3期 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构
分子式C2H8O7P2Re |
InChIKeyIRNIPRCGJQWCNJ-NLQOEHMXSA-N |
CAS号145571-93-3 |
使用我们的XDC技术数据为新药研发加速。
登录
或
关联
10
项与 铼[Re-188]依替膦酸盐 相关的临床试验评价铼[188Re]依替膦酸盐注射液在去势抵抗性前列腺癌骨转移患者中的药代动力学和药效学临床研究
多中心、随机、双盲、安慰剂平行对照评价[188Re]依替膦酸盐注射液对CRPC癌骨转移患者的耐受性、有效性和安全性
Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study
100 项与 铼[Re-188]依替膦酸盐 相关的临床结果
登录后查看更多信息
100 项与 铼[Re-188]依替膦酸盐 相关的转化医学
登录后查看更多信息
100 项与 铼[Re-188]依替膦酸盐 相关的专利（医药）
登录后查看更多信息
40
项与 铼[Re-188]依替膦酸盐 相关的文献（医药）2021-07-01International journal of clinical oncology3区 · 医学
Efficacy and safety of 188Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study
3区 · 医学
Article
作者: Liu, Zengli ; Li, Jun ; Chen, Ping ; Wu, Yiwei ; Kuai, Dayu ; Zhang, Guangming ; Liu, Xingdang ; Wang, Yuankai ; Gui, Jicong ; ZhangLi, Yingjian Biao ; Zuo, Changjing ; Lv, Zhongwei ; Liu, Congjin
PURPOSE:
To investigate the pain-relieving effect and safety of three different doses of 188Re-hydroxyethylidine diphosphonate (HEDP) in patients with lung cancer and bone metastases.
METHODS:
For this randomised, phase 2 and multicenter trial, we enrolled patients with lung carcinoma and multifocal bone metastases and excluded patients who had received bisphosphonates or external-beam radiotherapy within the previous 4 weeks. Fifty-four patients were randomized to receive a single injection of 188Re-HEDP, at doses of 30, 40 or 50 MBq/kg (interval, 12 weeks). Patients were followed-up by assessment of numerical rating scale (NRS) score, global quality of life (QOL) score and adverse events (AEs). ANOVA analysis, Chi-Squared test and LSD-t test were used in this study.
RESULTS:
Significantly decreased NRS scores relative to baseline were observed in 40 MBq/kg group (Week 0 vs. Week 12: 6.0 ± 1.4 vs. 4.8 ± 2.5, P = 0.033) and 50 MBq/kg group (Week 0 vs. Week 12: 5.5 ± 1.5 vs. 4.5 ± 2.9, P = 0.046). Significant change of global QOL score from baseline was observed in 40 MBq/kg group at week 8 (global QOL score: P = 0.024, pain score: P = 0.041) and 50 MBq/kg group (pain score: P = 0.021) at week 12. No patients withdrew trial because of AEs in three groups.
CONCLUSIONS:
188Re-HEDP at dose of 40 and 50 MBq/kg was generally effective to alleviate pain and improve QOL in lung cancer patients with painful bone metastases. 188Re-HEDP was safe and well-tolerated.
2018-10-01World journal of nuclear medicine
Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies
Article
作者: Mallia, Madhava ; Banerjee, Sharmila ; Kamaleshwaran, K ; Upadhyay, Indira ; Joseph, Jephy ; Kameswaran, Mythili ; Sairam, Madhu ; Dash, Ashutosh ; Shinto, Ajit ; Subramaniam, R ; Radhakrishnan, E
188Rhenium-hydroxyethylidene-1,1-diphosphonate (188Re-HEDP) is a clinically established radiopharmaceutical for bone pain palliation of patients with metastatic bone cancer. Herein, the effectiveness of 188Re-HEDP for the palliation of painful bone metastases was investigated in an uncontrolled initial trial in 48 patients with different types of advanced cancers. A group of 48 patients with painful bone metastases of lung, prostate, breast, renal, and bladder cancer was treated with 2.96–4.44 GBq of 188Re-HEDP. The overall response rate in this group of patients was 89.5%, and their mean visual analog scale score showed a reduction from 9.1 to 5.3 (P < 0.003) after 1 week posttherapy. The patients did not report serious adverse effects either during intravenous administration or within 24 h postadministration of 188Re-HEDP. Flare reaction was observed in 54.2% of patients between day 1 and day 3. There was no correlation between flare reaction and response to therapy (P < 0.05). Although bone marrow suppression was observed in patients receiving higher doses of 188Re-HEDP, it did not result in any significant clinical problems. The present study confirmed the clinical utility and cost-effectiveness of 188Re-HEDP for palliation of painful bone metastases from various types of cancer in developing countries.
2018-07-01World journal of nuclear medicine
188Re-HEDP therapy in the therapy of painful bone metastases
Review
作者: Liepe, Knut
For bone-targeted radionuclide therapy (BTRT), different commercial radiopharmaceuticals are available such as strontium-89, 186Rhenium-hydroxyethylidene diphosphonate (186Re-HEDP), Samarium-153-ethylenediamine tetramethylene phosphonic acid, and radium-223. Unfortunately, the commercial available radiopharmaceuticals are very expensive (from 1,200 to 36,000€ per patient in Europe). The 188W/188Re generator is an ideal source for the long-term (4–6 months) continuous availability of 188Re suitable for the preparation of radiopharmaceuticals for different radionuclide therapies. Labeling at HEDP, it can use cost-effective for BTRT, if enough patients are available for therapy. And so, 188Re-HEDP is the ideal candidate in developing countries which high population to replace the other agents. Two German groups documented a response rate of 80% without any severe side effects and similar bone marrow toxicity compared to the other compounds for 188Re-HEDP. Using 188Re-HEDP in repeated treatments, a prolonged overall survival of repeated to single application was observed (from 4.5 months for single to 15.7 months using ≥≥3 applications).
1
项与 铼[Re-188]依替膦酸盐 相关的新闻（医药）2024-07-07
·药事纵横
并购放射疗法财报
100 项与 铼[Re-188]依替膦酸盐 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期前列腺癌 | 临床3期 | 荷兰 | 2018-05-16 | |
| 转移性去势抵抗性前列腺癌 | 临床3期 | 荷兰 | 2018-05-16 | |
| 去势抵抗性前列腺癌 | 临床2期 | 中国 | 2020-06-15 | |
| 去势抵抗性前列腺癌 | 临床2期 | 中国 | 2020-06-15 | |
| 骨转移癌 | 临床2期 | 中国 | 2013-09-12 | |
| 骨转移癌 | 临床2期 | 中国 | 2013-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 12 | 襯鹹窪願蓋製壓齋構構(獵觸構鑰範鏇鬱製淵繭) = after the 2nd cycle of re-188 (thrombopenia grade 3 causing delay of the next cycle of treatment) 簾廠築壓夢鹹鏇構鑰鹽 (憲鏇鑰夢鏇齋憲窪鹹選 ) | - | 2016-05-20 | |||
N/A | 21 | 顧範範襯範膚範網淵鬱(觸齋鬱夢壓構築廠積鹽) = Relevant but reversible hematotoxicity (grade 3/4) occurred in 6 patients (28.5%) and 8 administrations (11.9%) with leukopenia and thrombocytopenia in 3% and anemia in 7.5% 觸醖積鹽餘遞齋糧窪窪 (醖鏇製淵顧獵醖簾簾鬱 ) | 积极 | 2014-11-05 | |||
N/A | 61 | 齋簾獵鹹製顧構鏇繭壓(淵遞築獵衊鏇艱夢鏇廠) = 構簾鑰糧鏇餘製醖鑰鹹 艱壓鏇願鹹餘築獵選艱 (簾壓製壓願選簾蓋夢餘 ) | 积极 | 2004-07-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用